KEYNOTE-013: PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure


KEYNOTE-013: PD-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Slides from a presentation at ASH 2014 and transcribed comments from recent interviews with Craig Moskowitz, MD (1/6/15) and Stephen M Ansell, MD, PhD (1/20/15)
Moskowitz CH et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a Phase 1b study (KEYNOTE-013). Proc ASH 2014;Abstract 290.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician for Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Medical College of Cornell University in New York, New York.

Dr Ansell is Professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota.